Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
EF 2022-23
Résumé
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer deaths. Despite curative surgical treatment options, post-operative disease recurrence remains a major obstacle to long-term survival. Our goal is to improve the outcomes of surgical intervention for HCC by developing a non-invasive blood-based assay for monitoring disease progression after liver resection or transplantation. We will achieve this goal by first analyzing the clonal genomic structure of tumor samples accrued from over 130 HCC patients, and later assessing whether genetic and epigenetic alterations can similarly be detected in circulating tumor DNA (ctDNA) extracted from serial blood draws. In patients with recurrent disease, we will compare the clonal composition of biopsies at relapse with the original surgical specimen to identify mechanisms which may drive the establishment of relapsed tumors in each treatment scenario. Upon successful completion of this work, we will have identified pre- and post-operative biomarkers which can be used to predict recurrence and treatment response, thus leading to improved patient stratification, outcomes, and allocation of scarce healthcare resources. We will also have elucidated basic mechanisms of cancer progression leading to relapse in HCC, particularly the repopulation of donor livers in relapsed transplant patients.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
485945
Name
oricchio kirsh bianca S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
na
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Cancer; Disease Recurrence; Early Detection; Genomics; Hepatocellular Carcinoma; Liquid Biopsy; Livery Cancer; Personalized Therapy
Abstract
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer deaths. Despite curative surgical treatment options, post-operative disease recurrence remains a major obstacle to long-term survival. Our goal is to improve the outcomes of surgical intervention for HCC by developing a non-invasive blood-based assay for monitoring disease progression after liver resection or transplantation. We will achieve this goal by first analyzing the clonal genomic structure of tumor samples accrued from over 130 HCC patients, and later assessing whether genetic and epigenetic alterations can similarly be detected in circulating tumor DNA (ctDNA) extracted from serial blood draws. In patients with recurrent disease, we will compare the clonal composition of biopsies at relapse with the original surgical specimen to identify mechanisms which may drive the establishment of relapsed tumors in each treatment scenario. Upon successful completion of this work, we will have identified pre- and post-operative biomarkers which can be used to predict recurrence and treatment response, thus leading to improved patient stratification, outcomes, and allocation of scarce healthcare resources. We will also have elucidated basic mechanisms of cancer progression leading to relapse in HCC, particularly the repopulation of donor livers in relapsed transplant patients.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
oricchio kirsh, bianca S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~